Gilead Sciences Stock Analysis (NASDAQ:GILD)

Add to My Stocks
$67.26 $0.16 (0.24%) GILD stock closing price Mar 29, 2017 (Closing)
Watch Robo Advisor Video of GILD Stock Analysis
Gilead Sciences
Updated on : Mar 29, 2017
previous close
GILD 67.3 (0%)
S&P 500 2361.1 (0%)
Closing Price On: Mar 29, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2016-Q4
$billion
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
58%
Sector Average:
-6.4%
5 Quarter Net Profit
Net Margins
2016-Q4
%
LTM Margin
Compared to the industry
Debt/Equity Ratio
Debt:
26.64B
Debt/Equity Ratio:
 1.38
Compared to the industry
Cash Flow
Operating cash flow:
$3.49B
Net Income:
$3.11B
Dividend Yield
GILD dividend yield:
2.74%
PROS      CONS
Operating Margins
Net Margins
ROIC
ROE
FCF Margin
PE Valuation
Recent Growth
High Debt Burden
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
GILD PS :
2.9
Industry PS :
4.7
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Invested Capital:
51.2%
Return on Equity:
78.5%
Free Cash Flow Margin:
45.3%
Double Tap To Exit Full Screen
0:00
/

Gilead Sciences Analysis Video

6700 9 2

View Gilead Sciences stock analysis video. This is our GILD analyst opinion covering the buy and sell arguments for GILD stock.

Gilead Sciences, Inc. Stock Rating (4.1/5)

Our Gilead Sciences stock opinion is based on fundamentals of the company. This Gilead Sciences stock analysis is based on latest Q4 earnings for 2016. The stock price analysis takes into account a company's valuation metrics.

Should you buy GILD stock?

  • The TTM operating margin was good at 58% for Gilead Sciences.
  • Net margins stood at a healthy 44.4% (average) for Gilead Sciences in the Trailing Twelve Months.
  • The Gilead Sciences stock currently trades at a price to earnings ratio of 5.9. We rate this as a positive, compared to the industry average of 21.5.
  • When compared with the Medical-Biomed-Genetics industry average PS ratio of 4.7, the price-to-sales ratio of 2.9 for GILD stock is attractive.
  • Gilead Sciences's return on invested capital of 51.2% is good.
  • The LTM ROE of 78.5% for Gilead Sciences is attractive.
  • Gilead Sciences has a healthy FCF (Free Cash Flow) margin of 45.3%.

Should you sell GILD stock?

  • Gilead Sciences revenue saw a decline of -13.9% YoY in 2016 Q4.
  • Gilead Sciences has a debt/equity ratio of  1.38, which is worse than the average in the Medical sector.

Comments on this video and Gilead Sciences stock